Friday December 1, 2023

Preclinical Translational Science: A View from Biotech

Christopher P. Austin, MD

CEO-Partner, Flagship Pioneering; CEO, Vesalius Therapeutics

Friday September 22, 2023

Gene Control Gene Control Medicines: Chemical Biology & Therapeutics

Jay Bradner, MD

Physician-Scientist and Former President, Novartis Institutes for BioMedical Research

Friday June 2, 2023

Nav1.7 as a Pain Target and Why Selective Nav1.7 Inhibitors

Have Not Yet Shown Efficacy in Clinical Trials

David H. Hackos, PhD

Senior Principal Scientist

Genentech, Inc.

Friday March 10, 2023

Preclinical Cancer Target Validation: How to Avoid Being Wrong 

(Even if You Fool Reviewer 3)

William G. Kaelin, Jr., MD

Sidney Farber Professor of Medicine

Harvard Medical School

Dana-Farber Cancer Institute and Brigham and Women’s Hospital,

Investigator, Howard Hughes Medical Institute

NOTE: The Nature article Common pitfalls in preclinical cancer target validation mentioned by Dr. Kaelin in this webinar is available here.